| 期 |
栏目 |
标题 |
文件 |
| 卷 27, 编号 2 (2021) |
Case reports |
A clinical case of the novel coronavirus (COVID-19) reinfection in a health care worker |
|
| 卷 27, 编号 6 (2021) |
Reviews |
Ghrelin as a promising biological marker in cardiovascular disease |
(Rus)
|
| 卷 27, 编号 6 (2021) |
Clinical medicine |
Blood serum concentration of troponin in patients with COVID-19 of various severities |
(Rus)
|
| 卷 28, 编号 1 (2022) |
Reviews |
Fibroblast growth factor 21 as a new tool in the multicomponent assessment of cardiovascular diseases |
(Rus)
|
| 卷 28, 编号 1 (2022) |
Clinical medicine |
Dynamics of echocardiographic parameters in patients with severe COVID-19 during hospitalization |
(Rus)
|
| 卷 28, 编号 3 (2022) |
Reviews |
Interleukin-18 and cardiovascular diseases: a literature review |
(Rus)
|
| 卷 28, 编号 5 (2022) |
Reviews |
Klotho protein and atherosclerotic cardiovascular diseases: prolonging the thread of life |
(Rus)
|
| 卷 29, 编号 3 (2023) |
Reviews |
Chemerin as a cardiovascular biological marker: Present and future |
(Rus)
|
| 卷 29, 编号 1 (2023) |
Reviews |
Coronary heart disease in patients with human immunodeficiency virus infection |
(Rus)
|
| 卷 29, 编号 2 (2023) |
Reviews |
Diagnostic and therapeutic aspects of neuregulin-1: A review |
(Rus)
(Eng)
|
| 卷 29, 编号 4 (2023) |
Reviews |
Current insights into the role of miRNA-125 in cardiovascular disease: potential biological markers and therapeutic targets |
(Rus)
|
| 卷 29, 编号 5 (2023) |
Reviews |
Relaxin as a biological marker and therapeutic target in heart failure |
(Rus)
|
| 卷 28, 编号 6 (2022) |
Reviews |
miRNA-122 as a new player in cardiovascular disease |
(Rus)
|
| 卷 30, 编号 1 (2024) |
Reviews |
Diagnostic, prognostic and therapeutic aspects of apelin in cardiovascular diseases |
|
| 卷 30, 编号 3 (2024) |
Case reports |
A clinical case of isolated non-compact left ventricular myocardium in a 29-year-old patient |
|
